Treatment of Susac’s syndrome

Susac JO, Hardimann JM, Selhorst JB: Microangiopathy of the brain and retina. Neurology 1979, 29:313–316.

Susac JO: Susac’s syndrome: the triad of microangiopathy of the brain and retina with hearing loss in women. Neurology 1994, 44:591–593.

Susac JO, Murtagh FR, Egan RA, et al.: MRI findings in Susac’s syndrome. Neurology 2003, 61:1783–1787.

Susac JO: Susac’s syndrome. AJNR Am J Neuroradiol 2004, 25:351–352.

Saenz R, Quan AW, Magalhaes A, Kish K: MRI of Susac’s syndrome. AJR Am J Roentgenol 2005, 184:1688–1690.

Gross M, Eliashar R: Update on Susac’s syndrome. Curr Opin Neurol 2005, 18:311–314.

Egan RA, Ha Nguyen T, Gass DM, et al.: Retinal arterial wall plaques in Susac syndrome. Am J Ophthalmol 2003, 135:483–486.

O’Halloran HS, Pearson PA, Lee WB, et al.: Microangiopathy of the brain, retina, and cochlea (Susac syndrome): a report of five cases and a review of the literature. Ophthalmoscopy 1998, 105:1038–1044.

Fialho D, Holmes P, Riordan-Eva P, et al.: A blinding headache falling on deaf ears (Susac’s syndrome). Pract Neurol 2002, 2:358–361.

Petty GW, Engel AG, Younge B, et al.: Retinocochleocerebral vasculopathy. Medicine (Baltimore) 1998, 77:12–40.

Petty GW, Matteson EL, Younge BR: Recurrence of Susac syndrome. Mayo Clin Proc 2001, 76:958–960.

Gass DJW, Tiedman J, Thomas MA: Idiopathic recurrent branch retinal artery occlusion. Ophthalmology 1986, 93:1148–1157.

Fox RJ, Costello F, Judkins AR, et al.: Treatment of Susac syndrome with gamma globulin and corticosteroids. J Neurol Sci 2006, 251:17–20.

Heiskala H, Somer H, Kovanen J, et al.: Microangiopathy with encephalopathy, hearing loss and retinal arteriolar occlusions: two new cases. J Neurol Sci 1988, 86:239–250.

Kaminska EA, Sadler M, Sangalang V, et al.: Microangiopathic syndrome of encephalopathy, retinal vessel occlusion, and hearing loss [abstract]. Can J Neurol Sci 1990, 17:241.

Monteiro MLR, Swanson RA, Coppeto JR, et al.: A microangiopathic syndrome of encephalopathy, hearing loss, and retinal arteriolar occlusions. Neurology 1985, 35:1113–1121.

Bogousslavsky J, Gaio J-M, Caplan LR, et al.: Encephalopathy, deafness and blindness in young women: a distinct retinocochleocerebral arteriolopathy? J Neurol Neurosurg Psychiatry 1989, 52:43–46.

Do TH, Fisch C, Evoy F: Susac syndrome: report of four cases and review of the literature. AJNR Am J Neuroradiol 2004, 25:382–388.

Magro CM: Susac’s syndrome: an autoimmune endotheliopathy. Paper presented at the 1st Susac’s Syndrome Symposium, held at Ohio State University, Columbus, OH, April 2005.

Crowson AN, Magro CM: The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. J Hum Pathol 1996, 31:515–519.

Crowe WE, Bove KE, Levinson JE, et al.: Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982, 25:126–129.

Kissel JT, Mendell JR, Rammohan KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986, 314:329–334.

Dalakas MC: Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995, 37:S74–S86.

Greenberg SA, Amato AA: Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol 2004, 17:359–364.

Gordon DL, Hayreh SS, Adams HP Jr: Microangiopathy of the brain, retina, and ear: improvement without immunosuppressive therapy. Stroke 1991, 22:933–937.

Turner BW, Digre KB, Shelton C: Susac syndrome. Otolaryngol Head Neck Surg 1998, 118:866–867.

Aubart-Cohen F, Klein I, Alexandra JF, et al.: Long-term outcome in Susac syndrome. Medicine (Baltimore) 2007, 86:93–102.

Tashima K, Uyama E, Hashimoto Y, et al.: Susac’s syndrome: beneficial effects of corticosteroid therapy in a Japanese case. Intern Med (Tokyo) 2001, 40:135–139.

Coppeto JR, Currie JN, Monteiro MLR, et al.: Syndrome of arterial-occlusive retinopathy and encephalopathy. Am J Ophthalmol 1984, 98:189–202.

MacFadyen DJ, Schneider RJ, Chisholm IA: A syndrome of brain, inner ear, and retinal microangiopathy. Can J Neurol Sci 1987, 14:315–318.

Papo T, Biousse V, Lehoang P, et al.: Susac syndrome. Medicine (Baltimore) 1998, 77:3–11.

Hahn JS, Lannin WC, Sarwal MM: Microangiopathy of brain, retina, and inner ear (Susac’s syndrome) in an adolescent female presenting as acute disseminated encephalomyelitis. Pediatrics 2004, 114:276–281.

Papeix C, Laloum L, Richet A, et al.: Susac’s syndrome: improvement with combined cyclophosphamide and intravenous immunoglobulin therapy. Rev Neurol (Paris) 2000, 156:783–785.

Erer S, Boz M, Taskapilioglu, et al.: The first Susac’s syndrome case in Turkey. J Neurol Sci 2006, 251:134–137.

Gruhn N, Pedersen LK, Nielsen NV: Susac’s syndrome: the first case report in a Nordic country, with an 8-year follow-up. Acta Ophthalmol Scand 2005, 83:757–758.

Rennebohm RM, Susac JO: Treatment of Susac’s syndrome. J Neurol Sci 2007, 257:215–220.

Susac JO, Egan RA, Rennebohm R, Lubow M: Susac’s syndrome: 19752005 microangiopathy/autoimmune endotheliopathy. J Neurol Sci 2007, 257:270–272.

Rennebohm R: Juvenile dermatomyositis. Pediatr Ann 2002, 31:426–433.

Klein-Gitelman MS, Waters T, Pachman LM: The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 2000, 13:360–368.

Dalakas MC: High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials. Neurol Sci 2003, 24:S256–S259.

Dalakas MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004, 102:177–193.

Ramanan AV, Campbell-Webster N, Ota S, et al.: The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroid. Arthritis Rheum 2005, 52:3570–3578.

Kameda H, Nagasawa H, Ogawa H, et al.: Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005, 32:1719–1726.

Riley P, Maillard SM, Wedderburn LR, et al.: Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004, 43:491–496.

Nakashima S, Mori M, Miyamae T, et al.: Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis [in Japanese]. Ryumachi 2002, 42:895–902.

Edge JC, Outland JD, Dempsey JR, et al.: Mycophenylate mofetil as an effective corticosteroid sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65–69.

Majithia V, Harisdangkul V: Mycophenylate mofetil (Cellcept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005, 44:386–389.

Nadiminti U, Arbiser JL: Rapamycin (sirolimus) as a steroid sparing agent in dermatomyositis. J Am Acad Dermatol 2005, 52(Suppl 1):17–19.

Hengstman GL, van den Hoogen FH, Barrera P, et al.: Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003, 50:10–15.

Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601–607.

Chiappetta N, Steier J, Gruber B: Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005, 11:264–266.

Fisler RE, Liang MG, Fuhlbrigge RC, et al.: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002, 47:505–511.

Austin HA III, Klippel JH, Balow JE, et al.: Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986, 314:614–619.